Application of mesenchymal stem cell apoptosis microvesicle combined hydrogel in preparation of mammalian skin repair product
The invention provides application of mesenchymal stem cell apoptosis microvesicles combined with hydrogel in preparation of mammalian skin repair products, and belongs to the technical field of regenerative medicine. In the invention, the mesenchymal stem cell apoptosis microvesicles can promote vascularization of new tissues and regulate the local immune microenvironment of receptor tissues so as to accelerate epithelization of skin wounds to promote healing. The hydrogel with good biocompatibility not only can effectively prevent the mesenchymal stem cell apoptosis microvesicles from losing, but also can ensure the biological activity of the mesenchymal stem cell apoptosis microvesicles. According to the invention, the mesenchymal stem cell apoptosis microvesicles and the hydrogel are combined for application, so that the utilization efficiency and the skin repair effect of the mesenchymal stem cell apoptosis microvesicles can be improved, and the biological function of the mesenchymal stem cell apoptosis microvesicles can be better played, thereby accelerating the healing of wounds and promoting the repair and regeneration of injured skin..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 25. März Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
QIU XINYU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-03-25, Last update posted on www.tib.eu: 2023-07-24, Last updated: 2023-07-28 |
|---|
| Patentnummer: |
CN114224917 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013788353 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013788353 | ||
| 003 | DE-627 | ||
| 005 | 20230728085515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013788353 | ||
| 035 | |a (EPA)CN114224917 | ||
| 035 | |a (EPA)80761805 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a QIU XINYU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of mesenchymal stem cell apoptosis microvesicle combined hydrogel in preparation of mammalian skin repair product |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-03-25, Last update posted on www.tib.eu: 2023-07-24, Last updated: 2023-07-28 | ||
| 520 | |a The invention provides application of mesenchymal stem cell apoptosis microvesicles combined with hydrogel in preparation of mammalian skin repair products, and belongs to the technical field of regenerative medicine. In the invention, the mesenchymal stem cell apoptosis microvesicles can promote vascularization of new tissues and regulate the local immune microenvironment of receptor tissues so as to accelerate epithelization of skin wounds to promote healing. The hydrogel with good biocompatibility not only can effectively prevent the mesenchymal stem cell apoptosis microvesicles from losing, but also can ensure the biological activity of the mesenchymal stem cell apoptosis microvesicles. According to the invention, the mesenchymal stem cell apoptosis microvesicles and the hydrogel are combined for application, so that the utilization efficiency and the skin repair effect of the mesenchymal stem cell apoptosis microvesicles can be improved, and the biological function of the mesenchymal stem cell apoptosis microvesicles can be better played, thereby accelerating the healing of wounds and promoting the repair and regeneration of injured skin. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a XUAN KUN |4 aut | |
| 700 | 0 | |a GUO JING |4 aut | |
| 700 | 0 | |a HAN BING |4 aut | |
| 700 | 0 | |a GUAN LINGXIA |4 aut | |
| 700 | 0 | |a BAN JINGHAO |4 aut | |
| 700 | 0 | |a WANG YIXUAN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 25. März |
| 773 | 1 | 8 | |g year:2022 |g day:25 |g month:03 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/80761805/publication/CN114224917A1?q=CN114224917 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 25 |c 03 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 25 |c 03 | ||